Hypoxia-inducible factor-1αPro-582-Ser polymorphism prevents iron deprivation in healthy blood donors

Blood Transfusion

Volumn 11, Issue 4, 2013, Pages 553-557

  Torti, Lorenza ^a,b   Teofili, Luciana ^a   Capodimonti, Sara ^a   Nuzzolo, Eugenia R ^a   Iachininoto, Maria Grazia ^a   Massini, Giuseppina ^a   Coluzzi, Serelina ^c   Tafuri, Agostino ^c   Fiorin, Francesco ^b   Girelli, Gabriella ^c   Zini, Gina ^a   Larocca, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Portogruaro and San Donà di Piave Hospitals   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Blood donors; Hypoxia inducible factor; Iron deficiency

Indexed keywords

FERRITIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; PROLINE; PROTEIN VARIANT; SERINE;

ADULT; ALLELE; ANEMIA; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DNA SEQUENCE; ERYTHROCYTE; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEPLETION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; NEUTROPHIL; POLYMERASE CHAIN REACTION; PREVENTION; PROTEIN POLYMORPHISM; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; WILD TYPE; YOUNG ADULT;

ADULT; AGED; ANEMIA; BLOOD DONORS; DONOR SELECTION; FEMALE; FERRITINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SEX CHARACTERISTICS;

EID: 84891951815     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0076-13     Document Type: Article

References (15)

1. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 14: 399-408.
2. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365: 537-47.
3. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011; 12: 9-22.
4. Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114: 2015-9.
5. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/ erythrocytoses. Haematologica 2005; 90: 109-16.
6. Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003; 24: 1779-83.
7. Percy MJ, Mooney SM, McMullin MF, et al. A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. Mol Cancer 2003; 2: 31.
8. Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 2012; 119: 2219-27.
9. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007; 25: 1048-53.
10. Zhao T, Lv J, Zhao J, Nzekebaloudou M. Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res 2009; 28: 159.
11. Chen Y, Fu L, Han Y, et al. Testosterone replacement therapy promotes angiogenesis after acute myocardial infarction by enhancing expression of cytokines HIF-1a, SDF-1a and VEGF. Eur J Pharmacol 2012; 684: 116-24.
12. Clifford SC, Astuti D, Hooper L, et al. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx and HIF-1a in renal cell carcinoma. Oncogene 2001; 20: 5067-71.
13. Prior SJ, Hagberg JM, Phares DA, et al. Sequence variation in hypoxia-inducible factor 1alpha (HIF1A): association with maximal oxygen consumption. Physiol Genomics. 2003; 15: 20-6.
14. Döring F, Onur S, Fischer A, et al. A common haplotype and the Pro582Ser polymorphism of the hypoxia-inducible factor-1alpha (HIF1A) gene in elite endurance athletes. J Appl Physiol 2010; 108: 1497-500.
15. Miasnikova GY, Sergueeva AI, Nouraie M, et al. The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia. Haematologica 2011; 96: 1371-4.